Company & Sponsor Intelligence
Takeda
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials12
Recruiting1
Completed11
Countries3
Therapeutic footprint
adhdalzheimersdepressionepilepsyother_neurologyparkinsonssleep_disorders
Indexed studies
NCT04940624A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome
epilepsy · United StatesPHASE3
epilepsy · United StatesPHASE3
NCT05932407A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With Depression
depression · JapanCOMPLETED
depression · JapanCOMPLETED
NCT02539134TAK-935 Multiple Rising Dose Study in Healthy Participants
epilepsy · United StatesPHASE1
epilepsy · United StatesPHASE1
NCT05687916A Study of TAK-861 in Participants With Narcolepsy Type 2
sleep_disorders · United StatesPHASE2
sleep_disorders · United StatesPHASE2
NCT05137704A Study on the Use of Healthcare Resources and Costs of Attention Deficit Hyperactivity Disorder (ADHD) in Adults in England
adhd · United KingdomCOMPLETED
adhd · United KingdomCOMPLETED
NCT05687903A Study of TAK-861 in Participants With Narcolepsy Type 1
sleep_disorders · United StatesPHASE2
sleep_disorders · United StatesPHASE2
NCT06538064A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care
other_neurology · United StatesRECRUITING
other_neurology · United StatesRECRUITING
NCT02497235A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935
epilepsy · United StatesPHASE1
epilepsy · United StatesPHASE1
NCT02669082The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patients With Major Depressive Disorder by Using Actigraphy
depression · JapanPHASE4
depression · JapanPHASE4
NCT02337725A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients
parkinsons · JapanPHASE3
parkinsons · JapanPHASE3
NCT00672620Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder
depression · United StatesPHASE3
depression · United StatesPHASE3
NCT00325728Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →